Actively Recruiting
Lattice Radiation Therapy Versus Conventional Radiation Therapy for the Palliation of Large Tumors
Led by University Health Network, Toronto · Updated on 2026-03-03
148
Participants Needed
1
Research Sites
110 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this randomized, phase III trial is to to determine if Spatially Fractionated Lattice Radiotherapy (SFRT) known as LATTICE therapy, leads to a greater reduction in pain or discomfort compared with conventional Radiation Therapy (RT) in patients with large tumours. This is evaluated by assessing if a greater proportion of patients who receive RT with SFRT will have an improvement in pain/discomfort at 30 days defined using the International Consensus Pain Response (ICPR) compared with those treated with conventional RT.
CONDITIONS
Official Title
Lattice Radiation Therapy Versus Conventional Radiation Therapy for the Palliation of Large Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of a solid tumor greater than 5 cm confirmed by pathology or imaging
- Tumor unsuitable for surgery or definitive radiation therapy
- Eastern Cooperative Oncology Group (ECOG) status between 0 and 4 within 14 days before randomization
- Requires palliative radiation therapy to a lesion larger than 5 cm
- Imaging within 90 days prior to randomization and CT simulation for radiation planning
- Able to understand and provide written informed consent
- Willing and able to complete baseline and post-treatment pain questionnaires and maintain a pain diary
- Not pregnant, not planning pregnancy, and not planning to father a child within 90 days
- Available for treatment and follow-up with complete documentation of treatment and adverse events
You will not qualify if you...
- Prior radiotherapy causing substantial overlap with the treatment area
- Need for urgent surgery before radiation treatment
- Confirmed pregnancy
- Hematologic primary malignancy
- Medical conditions preventing protocol treatment delivery (e.g., connective tissue disorders)
- Tumors over critical central nervous system areas, heart, or spinal cord causing compression
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Princess Margaret Cancer Center
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
Research Team
J
Jelena Lukovic, MD FRCPC MPH MRMD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here